Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases.
With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin brings a unique blend of scientific rigor, operational leadership, and business insight. He’s worked across the full lifecycle of drug development—from early strategy to commercialization—always with a focus on making a real impact for patients with unmet medical needs.
Justin is also a Harvard-trained chemist, graduating magna cum laude with highest honors, and he’s passionate about translating complex science into therapies that can truly change lives.
We recently sat down with Miquel Vila-Perello, CEO of SpliceBio, at Jefferies - during which the team picked up the Series B Raise of the Year at the 2025 ELAs for their $135million round earlier this year.
SpliceBio are a Barcelona-based gene therapy company using a proprietary Protein Splicing platform to address diseases caused by large genes that traditional AAV vectors can’t deliver. Their lead program, SB-007 for Stargardt disease, is currently being investigated in their Phase 1/2 ASTRA study, marking a key clinical milestone in a condition with no approved treatments.
It was great to sit down with Miquel and hear about his journey in biotech & the origins of SpliceBio. He also shared some advice for other scientific co-founders stepping into the CEO-hotseat & his take on why Barcelona is well positioned to be the next EU biotech hot-spot.
We were delighted to be joined by Jason Cole, a seasonedbiotechnology executive and the CEO of Zag Bio, a Cambridge-based biotech company taking a novel approach to autoimmune disease, onto The BioHub!
Jason brings more than two decades of leadership experience across the biotech industry, spanning company formation, drug development, corporate strategy, and commercialization. Before joining Zag Bio, he heldsenior executive roles at several innovative life-science companies, including bluebird bio, where he served in multiple leadership positions across strategy, operations, finance, and legal affairs. He has also led and advised emerging biotech companies as both a CEO and board member.
At Zag Bio, Jason is leading a bold effort to rethinkhow autoimmune diseases are treated. Their work aims to address the root cause of autoimmunity, with the potential for more durable and transformative therapies.
We’re excited to talk with Jason today about his careerjourney, the science behind Zag Bio, and what it takes to build the next generation of biotech innovation.
Today on The BioHub, I’m joined by Brendan Teehan, Chief Commercial Officer at Pacira BioSciences.
Brendan has spent three decades building and leading commercial teams across biopharma, from Johnson & Johnson to Amgen, Tesaro, and Acadia.
Now at Pacira, he’s driving the company’s mission to transform pain management through innovative non-opioid therapies.
In this conversation, we get into what inspired him to join Pacira, how the company has evolved, and how they’ve aligned the entire organization around a clear and bold mission. We also dive into leadership, culture, and the future of pain management.
Let’s get into it.
We recently spoke to Lance Baldo, CEO of Beacon Therapeutics, during the Jefferies Healthcare Conference.
Beacon's Vista ph3 trial for laru-zova, their AAV Gene Therapy for X-Linked Retinitis Pigmentosa, has completed enrolment with topline expected in mid-2026.
Listen in to hear about Lance's career, from roles with Roche in both Switzerland & New Zealand to a return to the US with Genentech's ophthalmology division, and how he's drawn on those experiences in his role as CEO of Beacon.
We also cover Lance's experience as a first-time CEO, and his advice for other executives making that transition, on topics as broad as fundraising, regulatory discussions, and team building.
And of course, we cover the story behind Beacon & their mission to deliver a step-change for XLRP patients globally.
Welcome to The BioHub Podcast.
I’m joined by Luba Greenwood, CEO of Gallop.
Luba’s one of the most respected voices in biotech — a three-time CEO, founder of Binney Street Capital at Dana-Farber, and a driving force behind Biotech Hangout.
We talk about Gallop’s mission, what it takes to build strong culture in tough markets, and the personal motivation behind her work after losing her mum to cancer.
It’s an inspiring and powerful conversation — let’s get intoit.
Today we’re joined by a leader at the forefront of next-generation immunotherapy — Dr. Christian Leisner. Christian is the CEO and co-founder of CDR-Life, a biotechnology company pioneering a new class of highly targeted T-cell engaging therapies designed to tackle some of the most difficult-to-treat cancers.
With a PhD in Biochemistry from ETH Zurich and a Master’s in Molecular Biology and Chemistry from Roskilde University in Denmark, Christian has built a career that bridges deep scientific expertise with strategic leadership. Before launching CDR-Life, he held key roles at Novartis, Alcon, and the biotech success story ESBATech, contributing to global development programs across oncology, ophthalmology, autoimmunity, and cardiovascular disease.
Today, Christian leads CDR-Life’s mission to unlock the potential of MHC-targeted immunotherapies — developing treatments designed to precisely attack tumor cells by recognizing intracellular antigens, long thought to be ‘undruggable.’ Under his leadership, the company is shaping what could become a transformational approach in the fight against cancer.
We’re thrilled to have him with us today to explore the science, the strategy, and the future of immunotherapy
We were delighted to welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub! Avacta are a clinical-stage biotech pioneering next-generation oncology therapies.
With a remarkable career spanning top pharmaceutical companies and cutting-edge biotech — from Immunocore and Rubius Therapeutics to Tmunity and CytoImmune — Christina brings a unique blend of medical expertise, scientific insight, and leadership acumen. At Avacta, she is driving the development of groundbreaking therapeutics, leveraging proprietary platforms like pre|CISION™, with the goal of bringing life-changing treatments from lab to clinic.
In this episode, we’ll explore her journey from clinician-scientist to biotech executive, the vision and science behind Avacta, and the challenges and opportunities in developing innovative cancer therapies in today’s evolving regulatory and commercial landscape.
Welcome to another Episode of The Biohub
Today, I’m joined by Jill Howe, Chief Financial Officer at Lineage Cell Therapeutics, a company developing groundbreaking allogeneic cell therapies for conditions like dry AMD, spinal cord injury, and hearing loss.
Jill’s career spans more than 20 years across some of biotech’s most successful companies, helping take both Receptos and Gossamer Bio public before stepping into her current role at Lineage.
We talk about what inspired her to join the company, how shehelps shape and protect Lineage’s culture, what excites her most about their pipeline, and her perspective on leadership and women in biotech.
Let’s get into it.
Welcome back to another episode of The BioHub, we were thrilled to introduce a guest whose career lies at the cutting edge of cell therapy, biotech leadership, and real-world impact. Abigail Jenkins is a visionary biotech CEO whose journey has taken her from pioneering the development of cell therapies to leading companies at the forefront of regenerative medicine.
Before stepping into her current role, Abigail served as CEO of Gamida Cell, where she guided the company through pivotal stages of clinical development, advanced its pipeline of therapies, and championed innovation in cell-based treatments for patients in need. Her leadership helped bring new hope to people suffering from life-threatening diseases — all while navigating the complexities of regulatory approval, scientific uncertainty, and market pressures.
On this episode we welcomed Cameron Turtle, CEO of Spyre Therapeutics during the Jefferies Healthcare conference.
Spyre are developing next-generation antibodies, engineered for prolonged activity in the body and formulated for delivery as monotherapies or combination therapies to validated inflammatory targets. Their approach has the potential to deliver uncompromising efficacy and convenience for patients in a number of autoimmune indications.
This podcast was recorded in November 2025. Comments made during this podcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Spyre Therapeutic, Inc.'s (“Spyre”) expectations regarding Spyre’s product candidates including their potential safety and efficacy, business and clinical trial plans, milestones and timelines. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to Spyre's SEC filings, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q. These forward-looking statements are only as of the date they were made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.
Today we’re joined by one of Europe’s most respected builders of biotechnology companies — Luc Dochez.
Luc is a scientist-turned-entrepreneur whose career has helped shape the next generation of therapies in oncology, rare diseases, and genetic medicine. Over the past two decades, he has co-founded and led multiple biotech companies, including Vico Therapeutics, Montis Biosciences, and Pharvaris, and he served as CEO of Tusk Therapeutics, guiding it all the way to its acquisition by Roche.
Before becoming a serial entrepreneur, Luc held senior leadership roles at Prosensa, TiGenix, and other pioneering biopharma firms, building a reputation for turning cutting-edge science into real therapeutic opportunities. Today, as a Managing Partner at DROIA Ventures, he invests in and mentors the startups pushing the boundaries of precision medicine.
With a background that spans pharmacy, business strategy, company formation, and venture capital, Luc brings a uniquely holistic perspective on how breakthrough therapies go from idea to impact.
On this episode we're joined by Andrea DiMella - VP & Head of Talent at Atlas Venture - to get her insight into the evolving talent landscape in biotechnology.
We talk through Andrea's transition from a laboratory scientist into a transformative TA leader through roles with Genentech, Biogen, Third Rock, and now Atlas Venture. Her learnings throughout this journey are shaping the TA strategy of some of the most exciting biotechs in the Atlas portfolio.
Tune in to hear more about Andrea's perspective on building influential teams & company creation, when to provide hands-on support & when to let C-teams 'fly solo', and of course, Andrea's take on AI in talent acquisition.
Rita is the CEO of Muna Therapeutics, a biotech company focused on discovering and developing therapies that restore the function of diseased neurons and slow or stop neurodegeneration.
In this conversation, we explore Rita’s career journey and what inspired their move into biotech leadership, as well as what first drew them to Muna Therapeutics. We talk about Muna’s scientific focus, how their approach to neurodegenerative diseases stands apart, and what it takes to lead a globally distributed team.
We also dive into the culture they’re building at Muna — one that encourages innovation and resilience — and look ahead at what’s next for the company over the coming year.
Today on The BioHub, I’m joined by Robert Hoffman, Chief Financial Officer of CytoDyn.
Robert is a true industry veteran — with decades ofexperience leading finance and strategy across some of biotech’s most recognizable names, from Arena to Heron and Kintara. Over his career he’s guided IPOs, spin-offs, fundraises, and M&A, all while serving on the boards of multiple biotech companies.
Now at CytoDyn, Robert is helping steer the company as itadvances its lead monoclonal antibody program.
This conversation is about leadership, staying motivated inbiotech’s toughest cycles, and the big vision for CytoDyn’s future.
Today, we’re joined by an extraordinary leader who has spent her career at the intersection of science, innovation, and human potential — Dr. Sheila Gujrathi.
Sheila is a physician, scientist, engineer, and biotech entrepreneur whose journey embodies both precision and purpose. She earned her Bachelor’s degree in Biomedical Engineering and her M.D. from Northwestern University, before completing her residency at Brigham and Women’s Hospital / Harvard Medical School and fellowships in Allergy and Immunology at UCSF and Stanford.
Her career has been defined by bold leadership and groundbreaking innovation — from leading global immunology programs at Bristol-Myers Squibb, to serving as Chief Medical Officer at Receptos, where she helped advance the drug Zeposia® to approval for multiple sclerosis and ulcerative colitis. She went on to co-found and serve as CEO of Gossamer Bio, and today she chairs the boards of Ventyx Biosciences and Lila Biologics, while serving as a director at Janux Therapeutics.
But beyond her professional success, Sheila is known for her authenticity, her advocacy for diversity and inclusion in biotech, and her belief in leading with empathy, curiosity, and courage. Through her writing and mentorship, she challenges us to bring our whole selves to our work — reminding us that science and leadership are at their best when they’re deeply human.
On this episode we're joined by the Co-Founder & CEO of Tr1X, David de Vries.
David and the team are building on the Nobel Prize winning research into T-reg cells of Fred Ramsdell, Shimon Sakaguchi, and Mary Brunkow, pushing that science forward by translating a Type-1 regulatory T cell program into the clinic with one goal - lasting immune balance for patients.
Their lead program TRX103 is in ph1/2 trials for GvHD and Refractory Crohn's, whilst they just received another IND clearance for TRX319, an allogeneic CD19 CAR-Tr1 therapy, to tackle Progressive MS. Tr1X pick hard problems on purpose & these indications demonstrate that.
David is an impressive leader, having co-founded Arine, and was nominated recently in BioSpace's 40 under 40 list. Tr1X are one to watch, we hope you'll enjoy the episode!
We were honoured to welcome Neha Krishnamohan, onto The BioHub.
Neha began her professional journey at Goldman Sachs in theHealthcare Investment Banking Group, focusing on mergers & acquisitions and strategic financings for biotech and med-tech companies. During her time there, she helped execute more than $100 billion in transactions across biopharma, diagnostics and tools.
Building on that foundation, Neha then moved into anoperational leadership role in biotech: she served as CFO and Executive Vice President of Corporate Development at Kinnate Biopharma, a precision-oncology company, where she led financial operations, business development and investor relations — working through strategic alternatives that culminated in asset transactions and acquisition.
Most recently, she joined Artiva Biotherapeutics, aclinical-stage company focused on off-the-shelf natural-killer (“NK”) cell therapies for autoimmune diseases and cancer, as CFO & EVP Corporate Development (April 2024). Her role is helping drive the company’s growthstrategy, financing, M&A and operational execution as Artiva scales its pipeline.
On this episode of the BioHub Podcast we’re joined by the CEO of Alzinova, Tord Labuda. Alzinova are a Gothenburg-based biotech developing an Alzheimer’s vaccine that's just received FDA IND approval and will soon step into ph2 trials.
Alzinova’s products have been developed using their proprietary AβCC peptide™ technology. The technology entails covalent restriction of the amyloid-β (Aβ) peptide so that it only forms the soluble (Aβ) toxins (oligomers/protofibrils) that play a central role in the disease process.
Alzinova's mission is to bring true disease-modifying therapy to Alzheimer’s patients. By using the proprietary AβCC technology, Alzinova can develop therapies that are unique in that they target Alzheimer’s disease-driving toxins of Aβ (“oligomers”) specifically.